Home » Newsletters » BioWorld Science

BioWorld Science

June 12, 2017

View Archived Issues

Lexicon Pharmaceuticals reports topline results from Tandem3 study of sotagliflozin

Promising in vitro data presented for GSK-830 at ICAAC

Survival increased with 131I-burtomab in central nervous system metastases of neuroblastoma

Medivir gives update on phase IIa extension study of MIV-711

RQx Pharmaceuticals and Genentech divulge bacterial spsB inhibitors

XBiotech discontinues phase III XCITE study of Xilonix

MRC Technology identifies MAP kinase-interacting serine/threonine-protein kinase 1 inhibitors

Pfizer presents immunogenic compositions for use in pneumococcal vaccines

Probiodrug reports phase IIa results on PQ-912 in early Alzheimer's disease

Phase III study of lurasidone in bipolar I depression meets primary endpoint

Metal-protein aggregate radioligand [18F]FL2-b shows brain uptake in nonhuman primates

University of Georgia and ArunA Biomedical patent neural cell extracellular vesicles

PeptiDream licenses Peptide Discovery Platform System technology to Shionogi

Norgine announces European launches of Lymphoseek

Lyvgen Biopharma Holdings presents anti-PD-1 antibodies

NIH funds collaborative New York Center for AIDS Research

Helsinn returns elsiglutide to Zealand Pharma

Basilea signs clinical study agreement with ABTC to explore use of BAL-101553 in glioblastoma

China FDA accepts fruquintinib NDA for advanced colorectal cancer

Eloxx Pharmaceuticals holds series C financing round

68Ga-NOTA-Aca-BBN(7-14) PET imaging shows promise in pediatric OPG

Takeda conducts phase I/II study of Sabin-based inactivated poliomyelitis vaccine

Boehringer Ingelheim initiates phase IIa study of BI-1467335 in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...